- Frightened workers self-isolating to protect vulnerable loved ones shouldn ’t be punishedby UNISON Health care news on March 14, 2024 at 8:26 am
The government must do more to protect key workers threatened with dismissal or put on unpaid leave if they’re off work self-isolating because of vulnerable relatives, says UNISON today (Wednesday). Anxious staff have come to UNISON with heartbreaking stories, terrified that if forced to go into work, they might take the virus home – with potentially devastating consequences. Local government and NHS employers have put agreements in place to protect the income of any staff off work because of the health of family members. But some employers – including councils and schools – are instead using Public Health England (PHE) guidance to compel frightened staff to go into work, says UNISON. The PHE guidance states that staff with shielding or clinically vulnerable family members can stil...
- FDA grants Breakthrough Therapy Designation for Roche ’s Esbriet (pirfenidone) in unclassifiable interstitial lung diseaseby Roche Investor Update on March 14, 2024 at 8:26 am
Basel, 3 March 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Esbriet ® (pirfenidone) for adults with unclassifiable interstitial lung disease (uILD). The designation was granted based on data from a Phase II trial, which studied the efficacy and safety of Esbriet in uILD[1]. The study represented the first randomised controlled trial to exclusively enroll patients with progressive fibrosing uILD.“Today’s milestone for Esbriet builds on our continued commitment to improving the standard of care for people living with fibrotic lung diseases,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “We look forward to disc...
- FDA Approves Kalydeco (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Ageby Drugs.com - New Drug Approvals on March 14, 2024 at 8:26 am
BOSTON--(BUSINESS WIRE)--Sep. 25, 2020-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) approved Kalydeco (ivacaftor) for use in children with cystic fibrosis (CF) ages four months to... (Source: Drugs.com - New Drug Approvals)
- BARNEY CALMAN: Cystic fibrosis sufferers finally get 'wonder drug' after endless talksby the Mail online | Health on March 14, 2024 at 8:26 am
Over the past six months, the MoS has lifted the lid on the secretive talks between NHS England and drug company Vertex on access to cystic fibrosis drugs. (Source: the Mail online | Health)
- Jamie Cary wins major CF award for her work as Certified Child Life Specialist at Upstate ’s Robert C. Schwartz Cystic Fibrosis Centerby SUNY Upstate Medical on March 14, 2024 at 8:26 am
Cary was one of only two individuals nationwide to receive the Mary M. Kontos Care Champion Award from the Cystic Fibrosis Foundation at the North American Cystic Fibrosis Conference (NACFC) in October 2020. (Source: SUNY Upstate Medical)